Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 12Neoplasms 10Carcinoma, Renal Cell 9Ovarian Neoplasms 7Carcinoma, Transitional Cell 7Neoplasm Metastasis 6Pancreatic Neoplasms 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Recurrence 3Lymphoma 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Melanoma 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Kidney Diseases 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1

Interventions

Alpelisib 4berzosertib 3Fulvestrant 3Everolimus 3parsaclisib 2Topotecan 2NVP-BKM120 2Cetuximab 2talazoparib 1sotorasib 1serabelisib 1ruxolitinib 1duvelisib 1dapagliflozin 1cobimetinib 1ceralasertib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Letrozole 1Irinotecan 1Goserelin 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hereditary Sensory and Autonomic Neuropathies × avelumab × Clear all
NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Pfizer

Phase 2 Terminated
202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡